EMA Authorised: Xelevia (sitagliptin) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The European Medicines Agency authorised Xelevia (sitagliptin) for the treatment of Type 2 diabetes mellitus. The product is marketed by Merck Sharp & Dohme B.V…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Xelevia (sitagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Merck Sharp & Dohme B.V.. Decision date: 24/11/2025